<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| BINV-18  
External submission from Genentech, Inc. based on the Food and Drug Administration (FDA) approval of companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with atezolizumab plus albumin-bound paclitaxel.  
Request including determination of tumor PD-L1 status to ensure appropriate patient selection for treatment with atezolizumab plus albumin-bound paclitaxel. | Based upon review of the data in the noted references and the FDA approval, the panel consensus was to include the following bullet in the workup for recurrent/stage IV breast cancer.  
"For triple negative breast cancer (TNBC), assess PD-L1 biomarker status on tumor-infiltrating immune cells to identify patients most likely to benefit from atezolizumab plus albumin-bound paclitaxel." | YES: 21  
NO: 0  
ABSTAIN: 1  
ABSENT: 7 |
| BINV-Q  
External submission from Genentech, Inc. based on FDA approval of atezolizumab in combination with albumin-bound paclitaxel for the treatment of patients with PD-L1-positive metastatic TNBC.  
Request inclusion of atezolizumab + nab-paclitaxel (option for patients with PD-L1-positive TNBC as an option under HER2-negative preferred regimens). | Based upon review of the data in the noted references and the FDA approval, the panel consensus was to add atezolizumab + albumin-bound paclitaxel (option for patients with PD-L1-positive TNBC) to the list of HER2-negative preferred regimens with the following footnote: "Patients with TNBC, assess PD-L1 biomarker status on tumor-infiltrating immune cells to identify patients most likely to benefit from atezolizumab plus albumin-bound paclitaxel." | YES: 21  
NO: 0  
ABSTAIN: 1  
ABSENT: 7 |
| BINV-L, BINV-P, and BINV-Q  
External submission from Genentech, Inc. based on FDA approval of trastuzumab and hyaluronidase-oysk | Based upon review of the data in the noted references and the FDA approval, the panel consensus was to add the following footnote on pages that include trastuzumab: Trastuzumab and hyaluronidase-oysk injection for subcutaneous use may be substituted for trastuzumab. It has different dosage and administration instructions compared to intravenous trastuzumab. Do not | YES: 19  
NO: 0  
ABSTAIN: 3  
ABSENT: 7 |
| subcutaneous (sc) injection in HER2-positive adjuvant and metastatic breast cancer. Request to consider FDA approval of trastuzumab and hyaluronidase-oysk sc injection in HER2-positive adjuvant and metastatic breast cancer and the supporting pivotal trial publications for inclusion into the guidelines. | substitute trastuzumab and hyaluronidase-oysk for or with ado-trastuzumab emtansine. See Submission for References. |